Receive our newsletter – data, insights and analysis delivered to you
  1. Clinical Trials Analysis
February 25, 2021

Coronary Artery Disease accounts for 12.5% share of global Cardiovascular clinical trial activity in 2020

Coronary Artery Disease (CAD) (Ischemic Heart Disease) accounted for a 12.5% share of the global clinical trials within the Cardiovascular therapy area in 2020, registering a decrease of 2.2% when compared with the last ten-year average of 14.7% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials for Coronary Artery Disease

Industry sponsored trials held a 41.8% share of all the clinical trials for Coronary Artery Disease indication in 2020, registering an increase of 11.9% when compared with the ten-year average of 29.9%. Non-industry sponsored trials accounted for a 58.2% share in 2020, marking a decrease of 11.9% over the ten-year average of 70.1%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Coronary Artery Disease trials

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Asia-Pacific was the top region for industry sponsored Coronary Artery Disease trials, accounting for a 56.3% share in 2020, when compared with the five-year average of 66.2% and ten-year average of 55.1%.

Europe was at the second position with a 39.1% share in 2020, over the five-year average of 33.8% and ten-year average of 40.0%, followed by North America with a 13.8% share in 2020, as against five-year and ten-year averages of 16.3% and 24.2% respectively.

South and Central America stood fourth with a 1.1% share in 2020, compared with the five-year average of 8.0% and ten-year average of 8.3%, followed by Middle East and Africa with a 1.1% share in 2020, over five-year and ten-year averages of 6.2% and 8.4% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Coronary Artery Disease trials, accounting for a 40.2% share in 2020, as against the five-year average of 35.5% and ten-year average of 23.9%.

Russia held a 24.1% share in 2020, over the five-year average of 11.3% and ten-year average of 15.7%, followed by the US with a 12.6% share in 2020, compared with the five-year and ten-year averages of 15.8% and 22.8% respectively.

Italy held a 6.9% share in 2020, as against the five-year average of 6.5% and ten-year average of 8.3%.

The UK held a 5.7% share in 2020, over the five-year and ten-year averages of 8.8% and 9.7% respectively.

Top regions of non-industry sponsored Coronary Artery Disease trials

Asia-Pacific was the top region for non-industry sponsored Coronary Artery Disease trials, accounting for a 62.6% share in 2020 when compared with the five-year average of 52.1% and ten-year average of 49.0%.

Europe was at the second position with an 18.3% share in 2020, over the five-year and ten-year averages of 22.2% and 26.0% respectively, followed by Middle East and Africa with an 8.7% share in 2020, as against the five-year average of 15.7% and ten-year average of 12.4%.

North America stood at the fourth position with a 7.0% share in 2020, compared with the five-year average of 11.4% and ten-year average of 13.6%, followed by South and Central America with a 3.5% share in 2020, over the five-year and ten-year averages of 2.3% and 2.4% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Coronary Artery Disease trials, accounting for a 34.8% share in 2020, as against the five-year average of 28.3% and ten-year average of 21.9%.

South Korea held a 12.2% share in 2020, over the five-year average of 7.4% and ten-year average of 8.1%, followed by Iran with a 7.8% share, compared with the five-year and ten-year averages of 13.0% and 9.6% respectively.

Japan held a 5.2% share in 2020, as against the five-year average of 10.0% and ten-year average of 12.8%.

Australia held a 4.3% share in 2020, over the five-year average of 2.2% and ten-year average of 2.3%.

Phase I trials lead industry sponsored clinical trials for Coronary Artery Disease in 2020

Phase I trials held a 61.8% share of industry sponsored clinical trials for Coronary Artery Disease in 2020, over the five-year average of 42.2% and ten-year average of 38.2%.

Phase II trials held a 23.6% share in 2020, as against the five-year average of 20.9% and ten-year average of 20.8%. Phase IV trials held a 13.5% share in 2020, compared with the five-year and ten-year averages of 25.9% and 25.2% respectively.

Phase III trials held a 1.1% share in 2020, over the five-year average of 11.0% and ten-year average of 15.8%.

Phase IV trials lead non-industry sponsored clinical trials for Coronary Artery Disease in 2020

Phase IV trials held a 45.2% share of non-industry sponsored clinical trials for Coronary Artery Disease in 2020, over the five-year average of 46.7% and ten-year average of 45.7%.

Phase II trials held a 23.4% share in 2020, as against the five-year average of 35.0% and ten-year average of 34.1%. Phase III trials held a 22.6% share, compared the five-year and ten-year averages of 14.2% and 15.3% respectively.

Phase I trials held a 8.9% share in 2020, over the five-year average of 4.1% and ten-year average of 4.9%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU